NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from Hebei Rimao Technology? Mail in a sample (US only) and let us test it.

Test my supply
+5 more ↓
59%
Finnrick rating
#403 of 457 ranked vendors
42 of 62 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Hebei Rimao Technology's purity-focus record is strongest on GHK-Cu identity/purity and recently improved Retatrutide, whose late batch-tagged results are cleaner than earlier misses. Tirzepatide trends weaker with late purity, fill, and identity failures, while BPC-157 and Tesamorelin are dispersed; recent volume helps, but batch gaps leave uncertainty.

methodology →
vendor intelligence report
Vendor Intelligence Report: Hebei Rimao Technology

A toy-export supplier profile is tied to a short-lived peptide channel through shared contacts, while the verified peptide domain has disappeared. The report follows COA links, forum handles, domains, and rebrand leads to separate historical HRM from current copycat risk.

22 pages6 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
89%
5
2
Retatrutide
$0.83
84%
22
3
Tirzepatide
$0.44
70%
18
5
Tesamorelin
$2.10
50%
5
6
BPC-157
$0.60
49%
6
7
TB-500
$1.30
36%
3
8
CJC-1295
$3.50
24%
3
9
DSIP
-
-
0
10
HGH
$0.60
-
0
12
MOTS-c
-
-
0
13
Survodutide
$2.30
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%19 Jan 2026: 64%2 Feb 2026: 63%6 Feb 2026: 58%9 Feb 2026: 58%9 Feb 2026: 59%9 Feb 2026: 58%11 Feb 2026: 60%11 Feb 2026: 60%11 Feb 2026: 61%11 Feb 2026: 61%11 Feb 2026: 61%18 Feb 2026: 61%18 Feb 2026: 61%18 Feb 2026: 60%18 Feb 2026: 61%20 Feb 2026: 57%20 Feb 2026: 57%20 Feb 2026: 57%20 Feb 2026: 57%22 Feb 2026: 57%25 Feb 2026: 57%26 Feb 2026: 57%26 Feb 2026: 57%26 Feb 2026: 57%1 Mar 2026: 56%1 Mar 2026: 56%1 Mar 2026: 56%1 Mar 2026: 57%1 Mar 2026: 57%4 Mar 2026: 57%23 Apr 2026: 57%23 Apr 2026: 57%23 Apr 2026: 56%5 May 2026: 56%6 May 2026: 57%6 May 2026: 58%8 May 2026: 58%9 May 2026: 59%26 Jun 2026: 59%26 Jun 2026: 59%7 Oct 2026: current 59%64%57%59%Jan 26Oct 26
Free peptide testing

Ordered peptides from Hebei Rimao Technology? Mail in a sample (US only) and let us test it.

Test my supply
Hebei Rimao Technology test history
COA-backed lab tests
1-10 of 64

About Hebei Rimao Technology test results from Finnrick

Hebei Rimao Technology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 8 peptides and 64 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Hebei Rimao Technology peptides in this dataset are BPC-157 (6 tests), Cagrilintide (2 tests) and CJC-1295 (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 64 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from Hebei Rimao Technology? Mail in a sample (US only) and let us test it.

Test my supply